Skip to main content
Andrew Scharenberg, MD, Pediatrics, Seattle, WA

AndrewMarkScharenbergMD

Pediatrics Seattle, WA

Pediatric Allergy

Professor, Pediatrics, University of Washington School of Medicine

Dr. Scharenberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Scharenberg's full profile

Already have an account?

  • Office

    4800 Sand Point Way Ne
    Seattle, WA 98105
    Phone+1 206-987-2000

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Pediatrics, 1990 - 1992
  • University of North Carolina at Chapel Hill School of Medicine
    University of North Carolina at Chapel Hill School of MedicineClass of 1990

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2000 - 2025
  • MA State Medical License
    MA State Medical License 1995 - 2000
  • DC State Medical License
    DC State Medical License 1993 - 1997
  • MD State Medical License
    MD State Medical License 1993 - 1995
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2008

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Enabling Gene-Edited, Regulatory-like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune Disorders
    Andrew M. Scharenberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Chemically Controlled, Immunosuppression-Resistant, Anti-Bcma CAR-T Cells for Treatment of Antibody-Mediated Autoimmunity 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
    Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy OfficerJune 8th, 2021
  • Casebia Advances Genetic Engineering with New Tools and Techniques
    Casebia Advances Genetic Engineering with New Tools and TechniquesApril 24th, 2019
  • Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board
    Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory BoardNovember 9th, 2018
  • Join now to see all